Nachrichten zur AstraZeneca PLC Aktie

Since Prime Minister Margaret Thatcher unleashed a wave of privatizations in the 1980s, the London Stock Exchange has been a…

Aradhana Sarin led deals to expand AstraZenecas drug pipeline, and transformed the finance function to improve employee retention and productivity.…

The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place …

…

…

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell”…

22 February 2024 Acquisition of Gracell completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html) of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a…

22 February 2024 11:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 20 February 2024, an…

…

Sodexo and AstraZeneca extend their global partnership for a further 5 years.…

22 February 2024 07:00 GMT AstraZeneca prices a $5bn bond offering AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced…

21 February 2024 07:00 GMT Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission AstraZeneca PLC (the Company) announced…

Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug…

Hamburg (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von Berenberg: Luisa Hector, Analystin von Berenberg, stuft die Aktie des britisch-schwedischen Pharmakonzerns AstraZeneca plc (ISIN: GB0009895292,…

HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Astrazeneca von 12500 auf…

1. Currys rejects low-ball £700mln offer, second bid emerges Currys PLC (LSE:CURY) rejected an unsolicited £700 million takeover offer from…

19 February 2024 Acquisition of Icosavax Completed AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage…

…

NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat Astrazeneca auf "Overweight" mit einem Kursziel…

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca auf "Sell" mit einem Kursziel von 9900 Pence belassen. Die…

FTSE 100 up 12 points at 7,724. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 12.24pm: UK-registered ship ‘at risk of sinking’ after Red...…

FTSE 100 up 6 points at 7,717. Currys takeover bid rejected. AstraZeneca surges. 10.44am: Gas slips on mild weather, oil continues to recede…

FTSE 100 up 21 points at 7,733. AstraZeneca, Rolls-Royce gain. Germany said to already be in recession. 3.57pm: Germany likely in recession -…

Currys takeover bid rejected Moneysupermarket nets strong insurance earnings FTSE 100 opens lower, AstraZeneca surges 9.16am: House prices see first…

FTSE 100 up 13 points at 7,725. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 1.22pm: In case you missed it… easyJet founder calls…

FTSE 100 up 10 points at 7,722. Currys centre of bidding war. AstraZeneca, Rolls-Royce surge. 11.33am: AstraZeneca, Rolls-Royce lead risers AstraZeneca led...…

FTSE 100 up 21 points at 7,732. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 3.30pm: YouGov chief departs in key election year YouGov...…

FTSE 100 up 6 points at 7,718. Currys takeover bid rejected. AstraZeneca surges. 9.50am: AstraZeneca: UBS sees sales boost from latest treatments As...…

FTSE 100 up 13 points at 7,725. Currys in centre of bidding war. AstraZeneca, Rolls-Royce surge. 2.25pm: Barclays gains on buyback reports Barclays PLC...…

Currys takeover bid rejected Moneysupermarket nets strong insurance earnings FTSE 100 opens lower, AstraZeneca surges 8.30am: AstraZeneca seen higher...…

19 February 2024 Tagrisso with the addition of chemotherapy approved in the  US for patients with EGFR-mutated advanced lung cancer Approval based on FLAURA2…

19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell…

19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First…

Toronto (www.aktiencheck.de) - Rating-Update: BMO Capital Markets stuft die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London Stock…

Large-cap European firms with a global footprint and strong balance sheets have outperformed the ‘Magnificent Seven’ US stocks and are…

Anzeige / WerbungAstraZeneca unter der LupeAstraZeneca ist einer der größten Arzneimittelhersteller weltweit. Ein international renommierter Pharmakonzern, der in 1999 aus…

…

AstraZeneca PLC (LSE:AZN) faced a blow on Friday after Deutsche Bank analysts downgraded the pharmaceuticals giant on what they labelled a…

Major Indices Update: FTSE 100 drops on AstraZeneca disappointment Dow trades close to record highs Nikkei 225 scales new 34-year…

FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research hat Astrazeneca nach Zahlen von "Hold" auf "Sell"…

FDA grants Fast Track to Ionis and AstraZenecas ATTR-CM treatment…

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.…

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZenecas (AZN) eplontersen for treating adults with transthyretin-mediated…

AZN earnings call for the period ending December 31, 2023.…

After AstraZeneca reported lower-than-expected profit, CEO Pascal Soriot spoke with Bloombergs Anna Edwards, Kriti Gupta and Guy Johnson. (Source: Bloomberg)…

…

Hurdles in bringing drugs to market in the UK is putting pharmaceutical companies off investing, said the chief executive officer…

AstraZenecas earnings top estimates but shares fall on core operating profit drop…

Astrazeneca says Catalent deal shows importance of in-house capacity…